This web site is part of the Business Intelligence Division of Informa PLC
Abeona Therapeutics, Inc.
Drug Names(s): EB201, EB 201, AAV-DJCOL7A1
Description: EB-201 is a novel, AAV-mediated gene editing and delivery approach to correct COL7A1 gene mutations in skin cells (keratinocytes). The inherited disease dystrophic epidermolysis bullosa is caused by recessive or dominant mutations in COL7A1, the gene encoding type VII collagen.
Additional information available to subscribers only: